Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca

Q: How long will it take to read this news story?

The story "Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca" has 477 words across 27 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca" was covered 3 hours ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 10 news stories per day. It's most recent story was published ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23647637</li><li>URL: https://beamstart.com/news/koreas-lunit-in-ai-powered-17319034705738</li></ul>

Korea Economic Daily Logo Korea Economic Daily 3h ago

Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca - Korea Economic Daily

Quick Summary:

Ken Nesmith, Lunit's chief business officer (CBO), said in a recent interview with The Korea Economic Daily that the Korean company has been picked as AstraZeneca’s sole partner to use AI technology to identify eligible patients to administer the global biopharma’s lung cancer medicine Tagrisso.

Lunit Inc., a South Korean artificial intelligence-powered cancer diagnostics company, has partnered with global biopharmaceuticals giant AstraZeneca plc.to enter the AI-powered lung cancer diagnostics market jointly.

On Monday, the two companies signed a formal strategic business cooperation agreement.“In recent competitive bidding, Lunit was chosen as the sole AI biomarker partner for non-small cell lung cancer (NSCLC).